# Study to Compare Exposure of TA Following Administration of FX006 or TAcs in Patients With OA of the Shoulder or Hip

> **NCT03382262** · PHASE2 · COMPLETED · sponsor: **Pacira Pharmaceuticals, Inc** · enrollment: 55 (actual)

## Conditions studied

- Osteoarthritis of the Shoulder
- Osteoarthritis of the Hip

## Interventions

- **DRUG:** FX006 32 mg
- **DRUG:** TAcs 40 mg

## Key facts

- **NCT ID:** NCT03382262
- **Lead sponsor:** Pacira Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-18
- **Primary completion:** 2018-10-09
- **Final completion:** 2018-10-09
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2024-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03382262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03382262, "Study to Compare Exposure of TA Following Administration of FX006 or TAcs in Patients With OA of the Shoulder or Hip". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03382262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*